Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duncan McArthur

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Rapid access towards follow-up NOP receptor agonists using a knowledge based approachRonald Palin, John K Clark, Louise Evans, et al.
Journal of Medicinal Chemistry|March 12, 2025
Optimization of Cyclophilin B-Targeted Tri-vector Inhibitors for Novel MASH TreatmentsMaria-Eleni Kouridaki, Jonathan Gillespie, John Robinson, et al.
Journal of Medicinal Chemistry|February 2, 2022
Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS SignalingTamas Yelland, Esther Garcia, Charles Parry, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2011
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonistsTakao Kiyoi, Julia M Adam, John K Clark, et al.
Cancer Research|October 4, 2018
A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in GlioblastomaJoanna L Birch, Karen Strathdee, Lesley Gilmour, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2011
Discovery of potent, soluble and orally active TRPV1 antagonists. Structure-activity relationships of a series of isoxazolesPaul Ratcliffe, Lynn Abernethy, Nasrin Ansari, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2011
Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonistsRonald Palin, Lynn Abernethy, Nasrin Ansari, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2011
Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidatePaul Ratcliffe, Julia M Adam, James Baker, et al.
Cancer Research|February 1, 2018
Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin CancerMathieu Unbekandt, Simone Belshaw, Justin Bower, et al.
Journal of Medicinal Chemistry|March 31, 2025
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of RasCharles W Parry, Francesca Pellicano, Alexander W Schüttelkopf, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Rapid access towards follow-up NOP receptor agonists using a knowledge based approachRonald Palin, John K Clark, Louise Evans, et al.
Journal of Medicinal Chemistry|March 12, 2025
Optimization of Cyclophilin B-Targeted Tri-vector Inhibitors for Novel MASH TreatmentsMaria-Eleni Kouridaki, Jonathan Gillespie, John Robinson, et al.
Journal of Medicinal Chemistry|February 2, 2022
Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS SignalingTamas Yelland, Esther Garcia, Charles Parry, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2011
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonistsTakao Kiyoi, Julia M Adam, John K Clark, et al.
Cancer Research|October 4, 2018
A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in GlioblastomaJoanna L Birch, Karen Strathdee, Lesley Gilmour, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2011
Discovery of potent, soluble and orally active TRPV1 antagonists. Structure-activity relationships of a series of isoxazolesPaul Ratcliffe, Lynn Abernethy, Nasrin Ansari, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2011
Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonistsRonald Palin, Lynn Abernethy, Nasrin Ansari, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2011
Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidatePaul Ratcliffe, Julia M Adam, James Baker, et al.
Cancer Research|February 1, 2018
Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin CancerMathieu Unbekandt, Simone Belshaw, Justin Bower, et al.
Journal of Medicinal Chemistry|March 31, 2025
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of RasCharles W Parry, Francesca Pellicano, Alexander W Schüttelkopf, et al.
Pageof 2